After the FED: Value Found in Global Pharma Stocks
The market recovered from bigger losses with the S&P down 0.7%. The FED said economic growth will be modest and made two decisions for a neutral policy : taking money from mortgage securities to buy treasuries and keeping its balance sheet unchanged. This means money will not be drained...
Life Science Tools and Dx: Caliper(CALP) and Celera (CRA)Report Results
Two companies that have been restructured through M&A announced yesterday. Celera(CRA) was added to our model portfolio recently at 7, traded down 2% to $6.75 on missed guidance and a net loss of (.08) compared to a loss of 39 cents the same quarter of previous year. Revenue guidance was...
Model Portfolio:Life Science Tools and Dx
Q1 P Original Price % Return Q 2 P 8/2/10 % Recom 3/29/10 P Ret. Abaxis ABAX 26.8 2/2/09 15 79 21.2 20.7 30 Celera CRA 6.8 3/28/10 7 6.49 6.85 -2 Exact Sci EXAS UR 4.2 Genomic Health GHDX UR 12.6 13.1 Genoptix GXDX UR 17.2 18.13 GenProbe GPRO 48 2/2/09 45 7 46.3 45.9 5 Illumina ILMN 39 2/2/09...
AACC Notes: Biomarkers for Cardiovascular Risk-hsCRP
Last week's Plenary Session from the AACC featured Paul Ridker.MD,MPH from Brigham and Women's Hospital ,Boston,MA speaking about Inflammation,hsCRP and Cardiovascular Prevention. The session reviewed data from the JUPITER trial for the use of statins in primary cardiovascular prevention. Dr....
Novartis(NVS) and Pathwork Dx Collaborate on Biomarkers
The Wall Street Journal reported on Friday that Novartis (NVS) will collaborate with Pathwork Diagnostics on the development of biomarkers across a range of cancer types that would capitalize on the trend to "match patients with the right medicines". Pathwork, a venture funded Company in...